Wolverine Trading, LLC Cel Sci Corp Put Options Transaction History

Wolverine Trading, LLC

11 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2023 Aug 23, 2023	BUY	$2.11 - $2.83 $21,944 - $29,432	10,400 New	10,400 $25,000
Q2 2022 Aug 15, 2022	SELL	$2.58 - $4.99 $4,386 - $8,483	-1,700 Reduced 10.0%	15,300 $68,000
Q1 2022 May 16, 2022	SELL	$3.93 - $7.7 $22,008 - $43,120	-5,600 Reduced 24.78%	17,000 $67,000
Q4 2021 Feb 14, 2022	SELL	$7.1 - $12.82 $62,480 - $112,816	-8,800 Reduced 28.03%	22,600 $170,000
Q3 2021 Nov 12, 2021	SELL	$7.64 - $12.49 $306,364 - $500,849	-40,100 Reduced 56.08%	31,400 $347,000
Q2 2021 Aug 06, 2021	BUY	$8.68 - $27.49 $46,004 - $145,697	5,300 Added 8.01%	71,500 $917,000
Q1 2021 May 14, 2021	BUY	$12.0 - $27.64 $794,400 - $1.83 Million	66,200 New	66,200 $1.03 Million
Q4 2020 Feb 12, 2021	SELL	$11.05 - $16.62 $508,300 - $764,520	-46,000 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$11.69 - $14.54 $104,041 - $129,405	8,900 Added 23.99%	46,000 $567,000
Q2 2020 Aug 13, 2020	BUY	$9.75 - $17.6 $119,925 - $216,480	12,300 Added 49.6%	37,100 $584,000
Q1 2020 May 11, 2020	BUY	$7.54 - $17.05 $186,992 - $422,840	24,800 New	24,800 $293,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Trading, LLC with notifications on news.